Welcome to our dedicated page for Neurosense Therapeutics SEC filings (Ticker: NRSNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to present SEC-related information for NeuroSense Therapeutics Ltd. in connection with the NRSNW symbol. NeuroSense is a clinical-stage biotechnology company that describes its focus as discovering and developing treatments for debilitating neurodegenerative diseases, including ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead candidate, PrimeC, is a novel extended-release oral formulation combining two FDA-approved drugs, ciprofloxacin and celecoxib, designed to target multiple mechanisms involved in ALS and Alzheimer's disease.
While no specific SEC filings are listed in the available data for this symbol, investors commonly look to regulatory documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K to better understand a company’s business description, risk factors and program updates. For a company like NeuroSense, such filings can provide additional detail on its clinical-stage pipeline, including PrimeC, and on its strategy to develop combined therapies targeting multiple pathways associated with neurodegenerative diseases.
On Stock Titan, the SEC filings page is designed to surface these documents as they become available from EDGAR, along with AI-powered summaries that explain key sections in clearer language. When filings are present, users can review disclosures on topics such as clinical development progress, research activities and other company updates, and can also access insider transaction reports on Form 4 when applicable.
As filings for NRSNW are recorded, this page will help organize them by form type and date, and AI-generated insights will highlight important points so readers can more quickly understand how NeuroSense describes its business, programs and associated risks in its official SEC documents.
NeuroSense Therapeutics reported that the Korean Intellectual Property Office granted Korean Patent Number 10-2969898 covering the composition of PrimeC, its lead drug candidate for amyotrophic lateral sclerosis (ALS). The patent covers PrimeC’s proprietary tablet formulation, manufacturing process, pharmacokinetic profile, and its use in treating ALS, and is expected to protect these aspects in South Korea through 2042.
The company describes this as strengthening its global intellectual property around PrimeC and aligning with its plan to advance into a pivotal Phase 3 PARAGON trial in ALS, for which it has already received U.S. FDA clearance. PrimeC is a novel oral combination of ciprofloxacin and celecoxib designed to target multiple ALS-related disease mechanisms, and earlier Phase 2b data showed slowing of disease progression, biomarker activity, and a reported survival benefit.
NeuroSense Therapeutics reported that the Korean Intellectual Property Office granted Korean Patent Number 10-2969898 covering the composition of PrimeC, its lead drug candidate for amyotrophic lateral sclerosis (ALS). The patent covers PrimeC’s proprietary tablet formulation, manufacturing process, pharmacokinetic profile, and its use in treating ALS, and is expected to protect these aspects in South Korea through 2042.
The company describes this as strengthening its global intellectual property around PrimeC and aligning with its plan to advance into a pivotal Phase 3 PARAGON trial in ALS, for which it has already received U.S. FDA clearance. PrimeC is a novel oral combination of ciprofloxacin and celecoxib designed to target multiple ALS-related disease mechanisms, and earlier Phase 2b data showed slowing of disease progression, biomarker activity, and a reported survival benefit.
NeuroSense Therapeutics reports that the Japan Patent Office has granted Japanese Patent 7857044 covering its lead ALS drug candidate, PrimeC. The patent includes 17 claims and protects PrimeC’s unique extended-release composition and manufacturing process through 2042, including its synchronized delivery of ciprofloxacin and celecoxib.
The company describes this patent as a key part of its global intellectual property portfolio and long-term commercialization strategy in Japan. PrimeC has shown clinical, biomarker, and survival benefits in a Phase 2b ALS study, and NeuroSense has FDA clearance to initiate the pivotal Phase 3 PARAGON trial, expected to enroll about 300 participants.
NeuroSense Therapeutics reports that the Japan Patent Office has granted Japanese Patent 7857044 covering its lead ALS drug candidate, PrimeC. The patent includes 17 claims and protects PrimeC’s unique extended-release composition and manufacturing process through 2042, including its synchronized delivery of ciprofloxacin and celecoxib.
The company describes this patent as a key part of its global intellectual property portfolio and long-term commercialization strategy in Japan. PrimeC has shown clinical, biomarker, and survival benefits in a Phase 2b ALS study, and NeuroSense has FDA clearance to initiate the pivotal Phase 3 PARAGON trial, expected to enroll about 300 participants.
NeuroSense Therapeutics reports a regulatory milestone for its ALS drug candidate PrimeC. The company recently held a constructive meeting with Health Canada to discuss potential regulatory pathways supporting a New Drug Submission (NDS) for treating amyotrophic lateral sclerosis.
NeuroSense presented additional clinical, biomarker, and long-term outcome data as previously requested by Health Canada, and outlined its proposed NDS strategy. The company expects an official response from Health Canada in the third quarter this year and plans to provide further updates on the Canadian regulatory process.
NeuroSense Therapeutics reports a regulatory milestone for its ALS drug candidate PrimeC. The company recently held a constructive meeting with Health Canada to discuss potential regulatory pathways supporting a New Drug Submission (NDS) for treating amyotrophic lateral sclerosis.
NeuroSense presented additional clinical, biomarker, and long-term outcome data as previously requested by Health Canada, and outlined its proposed NDS strategy. The company expects an official response from Health Canada in the third quarter this year and plans to provide further updates on the Canadian regulatory process.
NeuroSense Therapeutics Ltd. entered a definitive agreement for an insider-led PIPE private placement of $600,000 in ordinary shares. The company will sell 750,000 shares at $0.80 each, a price 6.7% above the April 27, 2026 closing share price.
CEO Alon Ben-Noon, CFO Or Eisenberg, and a significant existing shareholder each committed $200,000. The financing is expected to close during the week of May 3, 2026, subject to customary conditions. NeuroSense plans to use the proceeds for general corporate purposes ahead of upcoming clinical and regulatory milestones.
NeuroSense Therapeutics Ltd. entered a definitive agreement for an insider-led PIPE private placement of $600,000 in ordinary shares. The company will sell 750,000 shares at $0.80 each, a price 6.7% above the April 27, 2026 closing share price.
CEO Alon Ben-Noon, CFO Or Eisenberg, and a significant existing shareholder each committed $200,000. The financing is expected to close during the week of May 3, 2026, subject to customary conditions. NeuroSense plans to use the proceeds for general corporate purposes ahead of upcoming clinical and regulatory milestones.
NeuroSense Therapeutics Ltd. reported a leadership change in its medical team. Dr. Ferenc Tracik will step down as Chief Medical Officer effective April 27, 2026, but will remain involved with the company as an independent advisor.
The company states that his departure does not arise from any disagreement on operations, policies, or practices. In his advisory role, Dr. Tracik will continue to support clinical development and provide strategic medical guidance for the PrimeC program, including around an upcoming Pre-NDS meeting with Health Canada.
NeuroSense Therapeutics Ltd. reported a leadership change in its medical team. Dr. Ferenc Tracik will step down as Chief Medical Officer effective April 27, 2026, but will remain involved with the company as an independent advisor.
The company states that his departure does not arise from any disagreement on operations, policies, or practices. In his advisory role, Dr. Tracik will continue to support clinical development and provide strategic medical guidance for the PrimeC program, including around an upcoming Pre-NDS meeting with Health Canada.
NeuroSense Therapeutics Ltd. filed a Form 6-K to furnish a press release announcing that the Brazilian Patent and Trademark Office has granted Brazilian Patent No. 112024007727-6 covering the company’s proprietary PrimeC composition, a fixed-dose oral combination of ciprofloxacin and celecoxib.
The patent, which follows corresponding approvals in the U.S. and Australia, provides protection for PrimeC in Brazil and extends patent coverage through October 2042, supporting long-term development and potential commercialization in amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative indications. NeuroSense describes PrimeC as a synchronized, extended-release, multi-target therapy and notes it is preparing to initiate the PARAGON Phase 3 pivotal trial in ALS after positive Phase 2b results and FDA clearance.
NeuroSense Therapeutics Ltd. filed a Form 6-K to furnish a press release announcing that the Brazilian Patent and Trademark Office has granted Brazilian Patent No. 112024007727-6 covering the company’s proprietary PrimeC composition, a fixed-dose oral combination of ciprofloxacin and celecoxib.
The patent, which follows corresponding approvals in the U.S. and Australia, provides protection for PrimeC in Brazil and extends patent coverage through October 2042, supporting long-term development and potential commercialization in amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative indications. NeuroSense describes PrimeC as a synchronized, extended-release, multi-target therapy and notes it is preparing to initiate the PARAGON Phase 3 pivotal trial in ALS after positive Phase 2b results and FDA clearance.
NeuroSense Therapeutics Ltd. reported that Nasdaq has notified the company it is not in compliance with two continued listing standards. The company’s ordinary shares closed below the required $1.00 minimum bid price for 30 consecutive business days from February 18 through March 31, 2026.
Over the same period, NeuroSense’s market value of listed securities was below Nasdaq’s $35 million minimum. These notices do not immediately affect trading; the shares and warrants remain on The Nasdaq Capital Market under “NRSN” and “NRSNW.”
NeuroSense has 180 calendar days, until September 29, 2026, to regain compliance. It must achieve at least $1.00 closing bid and $35 million MVLS for a minimum of 10 consecutive business days for each metric, subject to Nasdaq’s discretion.
NeuroSense Therapeutics Ltd. reported that Nasdaq has notified the company it is not in compliance with two continued listing standards. The company’s ordinary shares closed below the required $1.00 minimum bid price for 30 consecutive business days from February 18 through March 31, 2026.
Over the same period, NeuroSense’s market value of listed securities was below Nasdaq’s $35 million minimum. These notices do not immediately affect trading; the shares and warrants remain on The Nasdaq Capital Market under “NRSN” and “NRSNW.”
NeuroSense has 180 calendar days, until September 29, 2026, to regain compliance. It must achieve at least $1.00 closing bid and $35 million MVLS for a minimum of 10 consecutive business days for each metric, subject to Nasdaq’s discretion.
Eisenberg Or reported acquisition or exercise transactions in this Form 4 filing.
NeuroSense Therapeutics Ltd. Chief Financial Officer Eisenberg Or received a grant of 200,000 restricted Ordinary Shares as equity compensation. The shares were granted at $0.00 per share and will vest in equal quarterly installments over a two-year period starting on March 26, 2026, provided he continues to serve the company on each vesting date. Following this award, he directly holds 1,254,050 Ordinary Shares.
Eisenberg Or reported acquisition or exercise transactions in this Form 4 filing.
NeuroSense Therapeutics Ltd. Chief Financial Officer Eisenberg Or received a grant of 200,000 restricted Ordinary Shares as equity compensation. The shares were granted at $0.00 per share and will vest in equal quarterly installments over a two-year period starting on March 26, 2026, provided he continues to serve the company on each vesting date. Following this award, he directly holds 1,254,050 Ordinary Shares.
NeuroSense Therapeutics Ltd. filed an initial Form 3 for Chief Financial Officer Or Eisenberg, detailing his existing equity interests in the company. The filing reports direct ownership of 573,126 Ordinary Shares, along with fully vested options and warrants over additional Ordinary Shares.
The Form 3 shows options to purchase 21,000 Ordinary Shares at an exercise price of $0.033 per share, expiring on June 21, 2031, which are noted as fully vested and exercisable. It also lists warrants to purchase 66,666 Ordinary Shares at an exercise price of $0.75 per share, expiring on August 14, 2029, acquired in an August 15, 2024 private placement.
NeuroSense Therapeutics Ltd. filed an initial Form 3 for Chief Financial Officer Or Eisenberg, detailing his existing equity interests in the company. The filing reports direct ownership of 573,126 Ordinary Shares, along with fully vested options and warrants over additional Ordinary Shares.
The Form 3 shows options to purchase 21,000 Ordinary Shares at an exercise price of $0.033 per share, expiring on June 21, 2031, which are noted as fully vested and exercisable. It also lists warrants to purchase 66,666 Ordinary Shares at an exercise price of $0.75 per share, expiring on August 14, 2029, acquired in an August 15, 2024 private placement.
NeuroSense Therapeutics Ltd. director Mandil-Levin Revital filed an initial ownership report showing option and share holdings in the company. The filing lists options to purchase 72,000 Ordinary Shares at an exercise price of $1.43 per share, expiring on March 10, 2032, which are fully vested and exercisable.
The report also shows direct ownership of several blocks of Ordinary Shares, including 52,526 shares, 60,000 shares, and 76,844 restricted shares. Certain restricted shares vest on December 30, 2026 and January 30, 2027, subject to continued service and potential acceleration upon achieving specified business milestones.
NeuroSense Therapeutics Ltd. director Mandil-Levin Revital filed an initial ownership report showing option and share holdings in the company. The filing lists options to purchase 72,000 Ordinary Shares at an exercise price of $1.43 per share, expiring on March 10, 2032, which are fully vested and exercisable.
The report also shows direct ownership of several blocks of Ordinary Shares, including 52,526 shares, 60,000 shares, and 76,844 restricted shares. Certain restricted shares vest on December 30, 2026 and January 30, 2027, subject to continued service and potential acceleration upon achieving specified business milestones.